Akumin EBITDA 2011-2025 | AKU

Earnings before Interest, Taxes, Depreciation, and Amortization (EBITDA), is an often used measure of a company's profitability. Financial analysts use EBITDA for a number of purposes including calculating simple valuations of a firm, estimating cash flows, and assessing debt servicing capability. The uses for EBITDA in financial analysis are numerous, but in practice should be more restrained. While EBITDA has some useful applications, it should be used with caution, as the problems with EBITDA are abundant and can lead to a number of misguided conclusions.^[1]

EBITDA is an important indicator for investors and analysts because it allows them to evaluate a company's operating profit without considering the impact of financial expenses, taxes, or non-cash depreciation and amortization. It provides better comparability between companies in different industries or with different tax conditions.

EBITDA is often used to assess a company's ability to generate cash flow and repay debts. It can also serve as a measure of a company's operational efficiency, as it shows how profitable the core business is, regardless of external factors such as interest or taxes.

However, it is important to note that EBITDA is not an official financial statement measure and can be defined and calculated differently by companies. Therefore, investors and analysts should exercise caution when using EBITDA as an evaluation tool and combine it with other financial metrics and information to get a more complete picture of a company's financial condition.

Annual EBITDA Akumin

2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
70.1 M	58.5 M	51.4 M	74 M	27.8 M	4.93 M	3.34 M	2.21 M	-	-	-	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
74 M	2.21 M	36.5 M

Quarterly EBITDA Akumin

2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
-21.2 M	-29.5 M	25.2 M	-	16.6 M	22.6 M	27.9 M	-	16 M	11 M	8.3 M	-	7.97 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
27.9 M	-29.5 M	8.49 M

References

Brockman, C. M., & Russell, J. W. (2012). EBITDA: use it... or lose it?. International Journal of Business, Accounting and Finance, 6(2), 84-93.

EBITDA of other stocks in the Diagnostics research industry

Issuer	EBITDA	Price	% 24h	Market Cap	Country
Centogene N.V. CNTG	-46 M	-	-6.23 %	$ 30.6 M	Germany
Brainsway Ltd. BWAY	-5 M	$ 19.29	-1.73 %	$ 99.4 M	Israel
Chembio Diagnostics CEMI	-21.1 M	-	0.22 %	$ 16.8 M	USA
Castle Biosciences CSTL	24.7 M	$ 40.09	-0.27 %	$ 1.11 B	USA
Burning Rock Biotech Limited BNR	-749 M	$ 21.26	-2.34 %	$ 229 M	China
Accelerate Diagnostics AXDX	-12.3 M	-	-61.36 %	$ 2.46 M	USA
Biocept BIOC	-30.3 M	-	-13.05 %	$ 7.29 M	USA
DarioHealth Corp. DRIO	-55.7 M	$ 10.04	-0.99 %	$ 285 M	Israel
Enzo Biochem ENZ	-11.1 M	-	-8.98 %	$ 14.8 K	USA
BioNano Genomics BNGO	-90 M	$ 1.52	-0.65 %	$ 1.93 M	USA
Danaher Corporation DHR	5.58 B	$ 231.47	0.28 %	$ 169 B	USA
Exact Sciences Corporation EXAS	-757 M	$ 101.54	-0.05 %	$ 18.8 B	USA
DexCom DXCM	784 M	$ 67.42	0.84 %	$ 26 B	USA
Oxford Immunotec Global PLC OXFD	-3.26 M	-	-	$ 562 M	Britain
HTG Molecular Diagnostics HTGM	-20.2 M	-	-20.0 %	$ 1.06 M	USA
Fulgent Genetics FLGT	-49 M	$ 27.01	-0.55 %	$ 817 M	USA
Global Cord Blood Corporation CO	652 M	-	-	$ 399 M	China
Fluidigm Corporation FLDM	-35.1 M	-	1.08 %	$ 308 M	USA
Genetic Technologies Limited GENE	-6 M	-	-	$ 7.1 B	Australia
Genetron Holdings Limited GTH	-518 M	-	0.12 %	$ 80.1 M	China
DermTech DMTK	-104 M	-	-11.32 %	$ 2.94 M	USA
PRA Health Sciences, Inc. PRAH	416 M	-	-	$ 10.7 B	USA
CareDx, Inc CDNA	-189 M	$ 19.73	-1.45 %	$ 1.06 B	USA
Celcuity CELC	-113 M	$ 102.61	0.25 %	$ 4.05 B	USA
Anixa Biosciences ANIX	-13.8 M	$ 3.42	3.64 %	$ 109 K	USA
Co-Diagnostics CODX	-41.5 M	$ 0.24	-1.79 %	$ 7.04 M	USA
IQVIA Holdings IQV	3.32 B	$ 226.02	0.39 %	$ 41 B	USA
Motus GI Holdings MOTS	-11.5 M	-	-34.28 %	$ 263 K	Israel
Guardant Health GH	-401 M	$ 102.38	-0.12 %	$ 12.6 B	USA
NeoGenomics NEO	-53 M	$ 12.3	-0.97 %	$ 1.56 B	USA
Neogen Corporation NEOG	-942 M	$ 7.14	-0.14 %	$ 1.55 B	USA
Aspira Women's Health AWH	-32.5 M	-	-6.19 %	$ 10.5 M	USA
National Research Corporation NRC	40.2 M	$ 18.81	-1.05 %	$ 462 M	USA
Heska Corporation HSKA	-6.33 M	-	-	$ 1.31 B	USA
OPKO Health OPK	-53.9 M	$ 1.3	-0.76 %	$ 902 M	USA
Organovo Holdings ONVO	-12.4 M	-	-2.3 %	$ 19.4 M	USA
OpGen OPGN	499 K	-	-16.95 %	$ 1.54 M	USA
Pacific Biosciences of California PACB	-323 M	$ 1.88	3.3 %	$ 477 M	USA
Mettler-Toledo International MTD	50.4 M	$ 1 417.16	0.18 %	$ 30.1 B	Schweiz
Illumina ILMN	-479 M	$ 135.32	-0.64 %	$ 21.5 B	USA
Charles River Laboratories International CRL	589 M	$ 203.16	0.14 %	$ 10.4 B	USA
ENDRA Life Sciences NDRA	-10.8 M	$ 5.1	-	$ 2.74 M	USA
Koninklijke Philips N.V. PHG	553 M	$ 26.98	0.37 %	$ 20 B	Niderland
Personalis PSNL	-57.3 M	$ 8.41	-0.12 %	$ 498 M	USA
PerkinElmer PKI	775 M	-	-0.91 %	$ 14.7 B	USA
Quidel Corporation QDEL	1.11 B	$ 28.91	1.12 %	$ 1.22 B	USA
Quest Diagnostics Incorporated DGX	1.84 B	$ 175.92	0.48 %	$ 19.5 B	USA
Biodesix BDSX	-28.7 M	$ 6.82	1.04 %	$ 884 M	USA
Precipio PRPO	-6.4 M	$ 23.89	2.56 %	$ 31 M	USA